Non-adherence to anti-osteoporotic medications in Taiwan: Physician specialty makes a difference

Journal of Bone and Mineral Metabolism

Volumn 31, Issue 3, 2013, Pages 351-359

  Yu, Shan Fu ^a   Yang, Tsong Shing ^a   Chiu, Wen Chan ^a   Hsu, Chung Yuan ^a   Chou, Ching Lan ^a   Su, Yu Jih ^a   Lai, Han Ming ^a   Chen, Ying Chou ^a   Chen, Chung Jen ^a   Cheng, Tien Tsai ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Medication adherence; Osteoporosis; Pharmacotherapy; Risk factors

Indexed keywords

ALENDRONIC ACID; CALCITONIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; STEROID;

AGED; ARTICLE; BONE DENSITOMETRY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; HIP FRACTURE; HUMAN; HYPERTENSION; INSURANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICATION COMPLIANCE; MEDICATION POSSESSION RATIO; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOPEDIC SPECIALIST; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; TAIWAN; TREATMENT REFUSAL;

AGED; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MEDICINE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PHYSICIANS; PROPORTIONAL HAZARDS MODELS; TAIWAN;

EID: 84878549425     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0424-2     Document Type: Article

References (35)

1. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3-13
2. Eastell R, Garnero P, Vrijens B, Van de Langerijt L, Pols H, Ringe J, Roux C, Watts N, Cahall D, Delmas P (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408
3. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocr Metab 89:1117-1123
4. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
5. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
6. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
7. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497
8. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37-55
9. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711-719
10. Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH (2004) Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol 31:1993-1995
11. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414-2419
12. Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M (2012) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 23:1053-1060
13. Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y (2007) Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 18:1421-1427
14. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501
15. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
16. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259-1269
17. Yu SF, Chou CL, Lai HM, Chen YC, Chiu CK, Kuo MC, Su YJ, Chen CJ, Cheng TT (2012) Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Int J Rheum Dis 15:297-305
18. Dawson-Hughes B, Lindsay R, Khosla S, Melton L, Tosteson A, Favus M, Baim S (2008) Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, DC
19. (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496-1503
20. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914-921
21. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217-2222
22. McBride CA, Shugars DA, DiMatteo MR, Lepper HS, O'Neil EH, Damush TM (1994) The physician's role. Views of the public and the profession on seven aspects of patient care. Arch Fam Med 3:948-953
23. Iversen MD, Vora RR, Servi A, Solomon DH (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34:72-81
24. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922-928
25. Lillard LA, Rogowski J, Kington R (1999) Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. Med Care 37:926-936
26. Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437
27. Thier SL, Yu-Isenberg K, Leas B, Cantrell C, DeBussey S, Goldfarb N, Nash D (2008) In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care 17:48-57
28. Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334-341
29. Korsic M, Grazio S (2008) Non-hip peripheral osteoporotic fractures: epidemiology and significance. Arh Hig Rada Toksikol 59:53-58
30. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943-1951
31. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1321
32. Cole RP, Palushock S, Haboubi A (1999) Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing. Women Health 29:101-115
33. Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, Nair K, Pathak A (2008) Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 54:394-402
34. Gorai I, Tanaka Y, Hattori S, Iwaoki Y (2010) Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women. J Bone Miner Metab 28:176-184
35. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocr Metab 92:1296-1304